Imam M, Ji J, Zhang Z, Yan S
Front Pharmacol. 2025; 15:1493188.
PMID: 39867656
PMC: 11757020.
DOI: 10.3389/fphar.2024.1493188.
Cong Y, Li N, Zhang Z, Shang Y, Zhao H
J Transl Med. 2025; 23(1):104.
PMID: 39844182
PMC: 11752808.
DOI: 10.1186/s12967-025-06121-1.
Chen Y, Li C, Li M, Han B
Cancer Med. 2024; 13(24):e70498.
PMID: 39676279
PMC: 11646948.
DOI: 10.1002/cam4.70498.
Zhang Z, Zhang H, Zhang Z, Sandai D, Lu P, Zhang H
Front Immunol. 2024; 15:1483498.
PMID: 39555060
PMC: 11563968.
DOI: 10.3389/fimmu.2024.1483498.
Zhang X, Tang B, Luo J, Yang Y, Weng Q, Fang S
Mol Cancer. 2024; 23(1):255.
PMID: 39543600
PMC: 11566504.
DOI: 10.1186/s12943-024-02130-8.
Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.
Jiang Y, Li H, Wu S, Jiang B, Zeng L, Tang Y
Biol Direct. 2024; 19(1):88.
PMID: 39369222
PMC: 11453086.
DOI: 10.1186/s13062-024-00531-9.
Identification of diagnostic markers and molecular clusters of cuproptosis-related genes in alcohol-related liver disease based on machine learning and experimental validation.
Li J, Wang Y, Wu Z, Zhong M, Feng G, Liu Z
Heliyon. 2024; 10(18):e37612.
PMID: 39315155
PMC: 11417179.
DOI: 10.1016/j.heliyon.2024.e37612.
A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis.
Zhu X, Zhang Z, Xiao Y, Wang H, Zhang J, Wang M
Heliyon. 2024; 10(15):e35404.
PMID: 39170145
PMC: 11336580.
DOI: 10.1016/j.heliyon.2024.e35404.
Cuproptosis in cancer: biological implications and therapeutic opportunities.
Li L, Zhou H, Zhang C
Cell Mol Biol Lett. 2024; 29(1):91.
PMID: 38918694
PMC: 11201306.
DOI: 10.1186/s11658-024-00608-3.
Butyrate inhibits the malignant biological behaviors of breast cancer cells by facilitating cuproptosis-associated gene expression.
Zhang L, Huang S, Yuan Y
J Cancer Res Clin Oncol. 2024; 150(6):287.
PMID: 38833016
PMC: 11150186.
DOI: 10.1007/s00432-024-05807-1.
Comprehensive analysis of the effects of the cuprotosis-associated gene on patient prognosis and tumor microenvironment in human cancer.
Zhang G, Wang N, Ma S, Tao P, Cai H
Transl Cancer Res. 2024; 13(2):714-737.
PMID: 38482443
PMC: 10928633.
DOI: 10.21037/tcr-23-1308.
Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).
Ai L, Yi N, Qiu C, Huang W, Zhang K, Hou Q
Int J Oncol. 2024; 64(5).
PMID: 38456493
PMC: 11000534.
DOI: 10.3892/ijo.2024.5634.
Identification of cuproptosis-related molecular classification and characteristic genes in ulcerative colitis.
Bai X, Zhang F, Zhou C, Yan J, Liang H, Zhu R
Heliyon. 2024; 10(2):e24875.
PMID: 38312708
PMC: 10835364.
DOI: 10.1016/j.heliyon.2024.e24875.
Triglyceride-glucose index is a risk factor for breast cancer in China: a cross-sectional study.
Zhang J, Yin B, Xi Y, Bai Y
Lipids Health Dis. 2024; 23(1):29.
PMID: 38279158
PMC: 10811843.
DOI: 10.1186/s12944-024-02008-0.
PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.
Feng Y, Huang Z, Song L, Li N, Li X, Shi H
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4911-4925.
PMID: 38165426
DOI: 10.1007/s00210-023-02928-1.
Research progress in cuproptosis in liver cancer.
Chen L, Liu D, Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(9):1368-1376.
PMID: 38044648
PMC: 10929866.
DOI: 10.11817/j.issn.1672-7347.2023.230083.
Cuproptosis: emerging biomarkers and potential therapeutics in cancers.
Wang M, Zheng L, Ma S, Lin R, Li J, Yang S
Front Oncol. 2023; 13:1288504.
PMID: 38023234
PMC: 10662309.
DOI: 10.3389/fonc.2023.1288504.
Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer.
Qi Y, Yao Q, Li X, Li X, Zhang W, Qu P
Sci Rep. 2023; 13(1):17790.
PMID: 37853210
PMC: 10584849.
DOI: 10.1038/s41598-023-44681-8.
Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma.
Wang J, Li S, Guo Y, Zhao C, Chen Y, Ning W
Funct Integr Genomics. 2023; 23(3):279.
PMID: 37610668
PMC: 10447603.
DOI: 10.1007/s10142-023-01210-0.
Identification of Three Cuproptosis-specific Expressed Genes as Diagnostic Biomarkers and Therapeutic Targets for Atherosclerosis.
Chen Y, Xu X, Lin L, Tian S, Wu G
Int J Med Sci. 2023; 20(7):836-848.
PMID: 37324184
PMC: 10266043.
DOI: 10.7150/ijms.83009.